Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Screening Sensitivity According to Breast Cancer Location.

Théberge I, Guertin MH, Vandal N, Côté G, Dufresne MP, Pelletier É, Brisson J.

Can Assoc Radiol J. 2019 May;70(2):186-192. doi: 10.1016/j.carj.2018.10.007. Epub 2019 Mar 8.

PMID:
30853307
2.

Breast cancer subtype and screening sensitivity in the Quebec Mammography Screening Program.

Perron L, Chang SL, Daigle JM, Vandal N, Theberge I, Diorio C, Lemieux J, Pelletier E, Brisson J.

J Med Screen. 2019 Sep;26(3):154-161. doi: 10.1177/0969141318816736. Epub 2018 Dec 20. No abstract available.

PMID:
30572782
3.

The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?

Théberge I, Vandal N, Guertin MH, Perron L.

Breast Cancer Res Treat. 2019 Apr;174(2):525-535. doi: 10.1007/s10549-018-05095-7. Epub 2018 Dec 18.

PMID:
30564969
4.

Mammography Clinical Image Quality and the False Positive Rate in a Canadian Breast Cancer Screening Program.

Guertin MH, Théberge I, Zomahoun HTV, Dufresne MP, Pelletier É, Brisson J.

Can Assoc Radiol J. 2018 May;69(2):169-175. doi: 10.1016/j.carj.2017.12.003.

PMID:
29706254
5.

Clinical Image Quality and Sensitivity in an Organized Mammography Screening Program.

Théberge I, Guertin MH, Vandal N, Daigle JM, Dufresne MP, Wadden N, Shumak R, Samson C, Langlois A, Larocque I, Perron L, Pelletier É, Brisson J.

Can Assoc Radiol J. 2018 Feb;69(1):16-23. doi: 10.1016/j.carj.2017.09.002.

PMID:
29458953
6.

Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease.

Theberge I, Bowdridge J, Forgie MA, Carrier M, Louzada M, Siquiera L, Rhodes M, Wells PS.

Thromb Res. 2017 Apr;152:4-6. doi: 10.1016/j.thromres.2017.02.003. Epub 2017 Feb 7. No abstract available.

PMID:
28192715
7.

Technologists' Characteristics and Quality of Positioning in Daily Practice in a Canadian Breast Cancer Screening Program.

Guertin MH, Théberge I, Zomahoun HT, Dufresne MP, Pelletier É, Brisson J.

Acad Radiol. 2016 Nov;23(11):1359-1366. doi: 10.1016/j.acra.2016.07.002. Epub 2016 Aug 24.

PMID:
27567127
8.

Detection Rate, Recall Rate, and Positive Predictive Value of Digital Compared to Screen-Film Mammography in the Quebec Population-Based Breast Cancer Screening Program.

Théberge I, Vandal N, Langlois A, Pelletier É, Brisson J.

Can Assoc Radiol J. 2016 Nov;67(4):330-338. doi: 10.1016/j.carj.2016.02.001. Epub 2016 Jul 21.

9.

PO-41 - Rivaroxaban is effective therapy for high risk cancer patients with venous thromboembolic disease.

Wells PS, Theberge IA, Bowdridge JC, Forgie MA, Carrier M.

Thromb Res. 2016 Apr;140 Suppl 1:S191-2. doi: 10.1016/S0049-3848(16)30174-8. Epub 2016 Apr 8.

PMID:
27161729
10.

Clinical image quality in daily practice of breast cancer mammography screening.

Guertin MH, Théberge I, Dufresne MP, Zomahoun HT, Major D, Tremblay R, Ricard C, Shumak R, Wadden N, Pelletier E, Brisson J.

Can Assoc Radiol J. 2014 Aug;65(3):199-206. doi: 10.1016/j.carj.2014.02.001. Epub 2014 Jun 16.

11.

Radiologist interpretive volume and breast cancer screening accuracy in a Canadian organized screening program.

Théberge I, Chang SL, Vandal N, Daigle JM, Guertin MH, Pelletier E, Brisson J.

J Natl Cancer Inst. 2014 Mar;106(3):djt461. doi: 10.1093/jnci/djt461. Epub 2014 Mar 5.

PMID:
24598715
12.

Contribution and performance of mobile units in an organized mammography screening program.

Fontenoy AM, Langlois A, Chang SL, Daigle JM, Pelletier É, Guertin MH, Théberge I, Brisson J.

Can J Public Health. 2013 Mar 7;104(3):e193-9.

13.

Volume of screening mammography and performance in the Quebec population-based Breast Cancer Screening Program.

Théberge I, Hébert-Croteau N, Langlois A, Major D, Brisson J.

CMAJ. 2005 Jan 18;172(2):195-9.

Supplemental Content

Loading ...
Support Center